Tagged with Global

Top 5 In 2019 PharmaBoardroom had the exclusive opportunity to speak with executives that are heading up some of European pharma’s top companies. These stakeholders provided insights into their visions and strategies for success and how they are embracing innovation as they forge ahead.      David Loew, Executive Vice President, Sanofi…

Hungary Gábor Orbán, CEO of Gedeon Richter, highlights the recent turnaround of the company’s performance, its exciting new collaboration with Allergan in the US market, and the landmark launch of Gedeon’s first company-developed biosimilar in Japan.   Our advancement in biotechnology has been a key development for Gedeon Richter this year…

Opinion Eurasia Group’s Aditya Bhattacharji tackles three more key geopolitical issues that global pharma needs to be cognizant of: the world’s leading drug regulators becoming increasingly strident and active beyond national borders; the impact that greater awareness and work on climate change could have on the industry; and the risks surrounding…

Hungary István Hodász, CEO of Egis Pharmaceuticals PLC, introduces the longstanding history of the company and its positioning as a leading manufacturer of value-added generics with a strong presence in the CEE market. Hodász goes on to highlight the company’s recent milestones, including manufacturing investments, portfolio acquisitions, new therapeutic area strategies,…

China PharmaBoardroom recently analysed the contents of 10 interviews conducted with country managers at multinational pharma companies in China. We found some underlying themes present in the majority of the interviews, giving an exclusive glimpse into what is currently at the top of the minds of pharma country managers in China.…

Global The IFPMA’s Greg Perry shares some of the key findings from a panel discussion on access to healthcare products at the 2019 World Health Summit in Berlin and the vital importance of cross-sector partnerships in driving access to medicines and vaccines across the globe.   In October I had the…

Janssen In this exclusive and wide-ranging interview, Janssen’s EMEA head Kris Sterkens outlines the company’s strategies in Europe, its increasing embrace of digital solutions, and the shift toward pre-emptive and precision treatments. Sterkens also highlights how Janssen is positioning itself in the emerging markets under his remit and how the ongoing…

France Olivier Laureau, global president of Servier Group, outlines the impact of recent acquisitions, the significance of Servier’s recently-opened commercial subsidiary in the US, the ongoing importance of France to the global group, and Servier’s unique value proposition as a privately-owned R&D-focused company.   The acquisition of Shire products also allowed…

Korea YD Global Life Science is a Korean biopharmaceutical company with ambitions to become a global leader in new drug development with USD 1 billion in revenues. Its founder & CEO, Jin Woo Lee explains his strategy to reach this goal by licensing-out promising compounds acquired from research institutions, developing an…

Diversity Annually, PharmaBoardroom conducts hundreds of interviews with global CEO’s, country managers and industry leaders in the pharma industry. While we have crossed paths with many inspiring females in these positions, out of the top 50 pharma companies, only 3 are headed by women. That is a mere 6% — this…

Top 10 2018 has been an exciting year in world health and our team has spanned the globe to bring you in-depth country reports and high profile interviews with leaders from the life science industry. Bringing you a diverse array of insights – from those spearheading the medical cannabis revolution to the…

Top 10 Geoffrey Guy, David Meek, Tae Han Kim, Pierre Moustial, Vivek Sharma, Antonio Portela and many other remarkable people that are shaping the global life sciences industry shared with PharmaBoardroom valuable insights on the companies they lead and their vision for the future.   Geoffrey Guy Geoffrey Guy is the chairman and founder…